This cause of treatment failure is particularly well established in pediatric and adult patients treated with CD19-directed CAR T cells for B-ALL, in which reported frequencies of CD19-negative escape after CAR T cell therapy range between 7% and 25% [17,189,191,192,193,194,195]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.